All In Biotech

Drug Trial Radar · NCT05186285

Single Ascending Dose Study of CM338 in Healthy Volunteers

A Single-dose, Randomized, Double Blind, Placebo-controlled, Dose-increasing Study to Evaluate the Safety, Tolerability, PK Characteristics, PD Effect, and Immunogenicity of CM338 Injection in Healthy Subjects.

Last checked: Nov 19, 2026Latest source record: Nov 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Dec 11, 2021

Primary completion

Jul 27, 2022

Study completion Jul 27, 2022

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jan 11, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was a single-center, randomized, double blind, placebo-controlled, single-dose, dose-increasing study to evaluate the safety, tolerability, PK characteristics, PD effect, and immunogenicity of CM338 injection administered intravenously or subcutaneously at different doses in healthy subjects.

Conditions

  • Healthy

Interventions

  • CM338Drug

    CM338 : a humanized monoclonal antibody.

  • PlaceboDrug

    Placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety : Incidence of Adverse Events (AEs).Time frame: Baseline up to Day 57

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PKUCare Luzhong Hospital

    Zibo, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.